According to Mars Finance, as reported by Business Wire, the Nasdaq-listed biotechnology company Equillium has announced the launch of a cryptocurrency reserve strategy, integrating its cryptocurrency funding reserve strategy as part of its broader financial and growth goals. As of June 30, 2025, the company's total cash and cash equivalents amount to approximately $11.5 million, and it has not yet disclosed which digital currencies it will purchase.